Home About us Contact
|
Home About us Contact | ||
|
|
||
Glaucoma Treatment (glaucoma + treatment)
Selected AbstractsProstanoids in the Therapy of GlaucomaCARDIOVASCULAR THERAPEUTICS, Issue 1 2006Naruhiro Ishida ABSTRACT Elevated intraocular pressure (IOP) is one of the most important risk factors for the development of glaucoma, which is a progressive optic neuropathy. Lowering IOP is currently the only therapeutic approach to the therapy of glaucoma. Since the use of pilocarpine eye drops for glaucoma treatment was reported in the late 1870s, academic researchers and pharmaceutical companies attempted to discover new drugs with more potent, prolonged, and safer IOP-reducing effects. These persistent efforts finally paid off, and prostanoids with FP-receptor agonist activity were found to be very potent IOP-lowering agents. To date, three prostanoids (latanoprost, travoprost and bimatoprost) have been launched in many countries, and now a new FP-receptor agonist, tafluprost, is entering clinical development. All of these prostanoids are superior to the ,-adrenoceptor antagonists in their IOP-lowering efficacy, and no severe side effects have been reported in their long-term clinical use. In addition, tafluprost may be expected to improve ocular blood flow. Hence, prostanoids currently occupy center stage among glaucoma medications. It cannot be denied that in terms of efficacy, safety, patient compliance, and medical economy prostanoids are currently the first-line medicines among ocular antihypertensive drugs. [source] Non-compliance in glaucoma treatment: a Hong Kong perspectiveACTA OPHTHALMOLOGICA, Issue 3 2009Jeffrey Pong No abstract is available for this article. [source] Unmet needs in the treatment of glaucoma related to compliance, tolerability and concomitant dry eyeACTA OPHTHALMOLOGICA, Issue 2008G HOLLO Purpose Compliance to long-term topical treatment of glaucoma can be less than optimal. This may decrease the efficacy of the treatment. This presentation summarises the unmet needs in the current topical treatment of glaucoma related to compliance, tolerability and concomitant dry eye and discusses the expectations for future therapies. Results Glaucoma is a life long conditions and its management is multifactorial. However, compliance to topical glaucoma treatment can be less than optimal. Forgetfulness and topical side effects have been identified as important reasons for non-compliance. Topical side effects decrease the quality of life of the patient, which impacts on compliance. Dry eye and glaucoma are often concomitant diseases. Therefore, it is advisable to consider the management of both diseases together for the optimal care for these patients. Preservative free preparations may have benefits for the long term treatment of glaucoma patients, especially those with dry/sensitive eyes. Conclusion Compliance remains a key issue in the management of glaucoma. Glaucoma and dry eye as concomitant diseases present specific challenges for the optimal care of the patient. [source] Mean standard deviations for common glaucoma treatmentsACTA OPHTHALMOLOGICA, Issue 1 2009William C. Stewart No abstract is available for this article. [source] | ||||||||||